Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (51-60 of 174) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2018
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced CancerJohanna C Bendell, Anna M Varghese, David M Hyman, et al.
Haematologica|February 24, 2018
Single-agent dabrafenib for <i>BRAF</i><sup>V600E</sup>-mutated histiocytosisAnkush Bhatia, Gary Ulaner, Raajit Rampal, et al.
Plos One|May 13, 2015
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor InvasionThapi D Rao, Huasong Tian, Xun Ma, et al.
Breast Cancer Research and Treatment|November 3, 2016
Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer familyCiyu Yang, Angela G Arnold, Magan Trottier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid TumorsDavid M Hyman, Naiyer Rizvi, Ronald Natale, et al.
Molecular Cancer Research : MCR|December 15, 2015
Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAFJaclyn F Hechtman, Ahmet Zehir, Rona Yaeger, et al.
Gynecologic Oncology|May 15, 2012
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinomaDavid M Hyman, Kara C Long, Edward J Tanner, et al.
Cancer|August 30, 2012
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancerRachel N Grisham, Gopa Iyer, Karuna Garg, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Gynecologic Oncology|January 18, 2017
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231DDavid M Hyman, Michael W Sill, Heather A Lankes, et al.
Pageof 18

Showing results (51-60 of 174) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2018
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced CancerJohanna C Bendell, Anna M Varghese, David M Hyman, et al.
Haematologica|February 24, 2018
Single-agent dabrafenib for <i>BRAF</i><sup>V600E</sup>-mutated histiocytosisAnkush Bhatia, Gary Ulaner, Raajit Rampal, et al.
Plos One|May 13, 2015
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor InvasionThapi D Rao, Huasong Tian, Xun Ma, et al.
Breast Cancer Research and Treatment|November 3, 2016
Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer familyCiyu Yang, Angela G Arnold, Magan Trottier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid TumorsDavid M Hyman, Naiyer Rizvi, Ronald Natale, et al.
Molecular Cancer Research : MCR|December 15, 2015
Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAFJaclyn F Hechtman, Ahmet Zehir, Rona Yaeger, et al.
Gynecologic Oncology|May 15, 2012
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinomaDavid M Hyman, Kara C Long, Edward J Tanner, et al.
Cancer|August 30, 2012
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancerRachel N Grisham, Gopa Iyer, Karuna Garg, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Gynecologic Oncology|January 18, 2017
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231DDavid M Hyman, Michael W Sill, Heather A Lankes, et al.
Pageof 18